Tirzepatide is a novel dual GIP \ GLP-1. GIP and GLP-1 are both hormones secreted by the intestine, which can promote insulin secretion. Tirzepatide integrates two insulin promoting effects into a single molecule, representing a new class of drugs for the treatment of type 2 diabetes.
Tirzepatide and semaglutide have a similar sequence, with the lys side chains in the sequence modified with PEG, which are functional groups of peptides and can increase the water solubility of the sequence. The main physiological function of Tirzepatide is glucose dependent insulin nutritional polypeptide (GIP) and glucagon like peptide-1 (GLP-1) receptor dual agonist, which is being developed for the treatment of type 2 diabetes and has entered the clinical stage.
Tirzepatide significantly improves blood sugar control and weight, without increasing the risk of hypoglycemia.
Post time: Mar-28-2024